Pharsight

Application	Filing Date	Opposition Party	Legal Status

EP06706682A	2017-12-19	G. L. Pharma GmbH	Revoked
EP07751984A	2010-08-10	Straus, Alexander	Revoked
EP2005006983W	2009-10-13	Sanofi-Aventis Deutschland GmbH	Patent maintained as amended
EP2005006983W	2009-10-13	Ypsomed AG	Patent maintained as amended
EP04763833A	2008-03-27	Purdue Pharma LP	Opposition rejected
EP04763834A	2007-12-14	Purdue Pharma LP	Opposition rejected

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US8329216	August, 2014	FWD Entered	Endo Pharmaceuticals, Inc.	Amneal Pharmaceuticals, LLC
US8309122	January, 2014	Terminated-Denied	Endo Pharmaceuticals, Inc.	Amneal Pharmaceuticals, LLC
US8329216	January, 2014	FWD Entered	Endo Pharmaceuticals, Inc.	Amneal Pharmaceuticals, LLC
US7851482	December, 2013	Decision	Jen-Sen Dung et al
US7851482	November, 2013	Terminated-Settled	Endo Pharmaceuticals Inc.	Amneal Pharmaceuticals, LLC
US8309122	July, 2009	Decision	Huai-Hung Kao et al

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7851482	ENDO PHARMS	Method for making analgesics	Jul, 2029 (5 years from now)
US8871779	ENDO PHARMS	Process for preparing morphinan-6-one products with low levels of α,β-unsaturated ketone compounds	Nov, 2029 (6 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8329216	ENDO PHARMS	Oxymorphone controlled release formulations	Feb, 2023 (7 months ago)
US8309112	ENDO PHARMS	Coatings for implantable medical devices comprising hydrophilic substances and methods for fabricating the same	Feb, 2023 (7 months ago)
US8309122	ENDO PHARMS	Oxymorphone controlled release formulations	Feb, 2023 (7 months ago)
US7276250	ENDO PHARMS	Sustained release formulations of oxymorphone	Feb, 2023 (7 months ago)
US8075872	ENDO PHARMS	Abuse-proofed dosage form	Nov, 2023 (a month from now)
US8309060	ENDO PHARMS	Abuse-proofed dosage form	Nov, 2023 (a month from now)
US8114383	ENDO PHARMS	Abuse-proofed dosage form	Aug, 2024 (10 months from now)
US8192722	ENDO PHARMS	Abuse-proof dosage form	Sep, 2025 (1 year, 11 months from now)
US8808737	ENDO PHARMS	Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment	Jun, 2027 (3 years from now)

Opana Er is owned by Endo Pharms.

Opana Er contains Oxymorphone Hydrochloride.

Opana Er has a total of 11 drug patents out of which 4 drug patents have expired.

Expired drug patents of Opana Er are:

Opana Er was authorised for market use on 22 June, 2006.

Opana Er is available in tablet, extended release;oral dosage forms.

Opana Er can be used as relief of moderate to severe pain, dose modification for renal impairment.

The generics of Opana Er are possible to be released after 22 November, 2029.

Market Authorisation Date: 22 June, 2006

Treatment: Relief of moderate to severe pain; Dose modification for renal impairment

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
5MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
7.5MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
10MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
15MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
20MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
30MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
40MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued

OPANA ER family patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic